At date of last update were not found published data on its excretion into breast milk,
Pharmacokinetic data (low protein-binding capacity) make likely excretion into breast milk in amounts that could be significant.
Until more information on this drug is available, it is preferred other options that are known to be safer, especially during the neonatal period or in cases of prematurity.
Because of a small dose and low absorption to the plasma in a majority of ophthalmic preparations that are topically used, a significant excretion into the milk is unlikely, thus it is considered of very low risk while breastfeeding in this cases. It would be advisable to press on the lacrimal area or tightly close the eyes for a couple of minutes (nasolacrimal occlusion) to minimize the systemic absorption.
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
- Carteolol Hydrochloride
- Картеолола Гидрохлорид (Cyrillic)
- カルテオロール塩酸塩 (Japanese)
- Tamargo Menéndez J, Delpón Mosquera E. Farmacología de los bloqueantes de los receptores β-adrenérgicos. Curso βeta 2011 de Actualización en Betabloqueantes. 2011 Full text (in our servers)
- Carteolol. Ficha técnica. 2009 Full text (in our servers)
- Renard P, Kovalski JL, Cochereau I, Jaulerry S, Williamson W, Elena PP, Lablache Combier M, Allaire C, Siou-Mermet R. Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2005Abstract
- Riant P, Urien S, Albengres E, Duche JC, Tillement JP. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol. 1986Abstract
- Ishizaki T, Ohnishi A, Sasaki T, Kushida K, Horai Y, Chiba K, Suganuma T. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent. Eur J Clin Pharmacol. 1983Abstract